Medlab Clinical has obtained a New South Wales (NSW) Government grant for developing a proof-of-concept (PoC) NanoCelle Nasal RNA vaccine for Covid-19.
The grant is part of Australia’s requirement to build infrastructure and production to fight the pandemic.
The NanoCelle non-invasive vaccine delivered nasally is regarded as the ‘first in class’ therapeutic delivery system.
In partnership with the University of NSW (UNSW) and Macquarie University (MQ), the company will develop the vaccine for Covid-19 potential epidemics in future.
Medlab CEO Dr Sean Hall said: “This grant and collaboration with our university partners offer a welcomed patient solution, as well as a de-risked mechanism to spearhead NanoCelle into complex vaccine technologies.”
“The ability to prove the efficacious delivery of vaccines without the ‘jab’ is a serious game-changer to modern medicine, we are thrilled to be part of this and welcome the potential commercial opportunities ahead.”
Patented by the company in 43 nations, NanoCelle is a sub-micron delivery platform leveraged to improve therapeutics.
Irrespective of the active pharmaceutical ingredient (API), this platform is created to overcome the inadequacies posed by present standard delivery systems.
It permits APIs to be delivered directly into the bloodstream through oral-buccal, sublingual, intranasal and transdermal or topical routes.
In April last year, the European Patent Office issued an Intention to Grant notice to Medlab for its patent covering the usage of NanoCellesub-micron delivery platform in the region and in the UK.
Earlier in September 2020, the company obtained an Australian patent for the NanoCelle platform.
Furthermore, the platform provides a market-ready delivery solution with patent protection until 2036 in Australia, Canada, New Zealand, the UK and Europe.